These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29029185)

  • 1. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
    Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; Hendriks L; Denissen NHAM; van Laar JM; Lafeber FPJG; Bijlsma JWJ
    Rheumatology (Oxford); 2017 Dec; 56(12):2179-2189. PubMed ID: 29029185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.
    Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; van Laar JM; Lafeber FPJG; Bijlsma JWJ
    Rheumatology (Oxford); 2018 Feb; 57(2):309-317. PubMed ID: 29095992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
    Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
    Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.
    Strand V; Burmester GR; Ogale S; Devenport J; John A; Emery P
    Rheumatology (Oxford); 2012 Oct; 51(10):1860-9. PubMed ID: 22753773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
    Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
    Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
    Teitsma XM; Yang W; Jacobs JWG; Pethö-Schramm A; Borm MEA; Harms AC; Hankemeier T; van Laar JM; Bijlsma JWJ; Lafeber FPJG
    Arthritis Res Ther; 2018 Oct; 20(1):230. PubMed ID: 30322408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
    Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
    Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
    Arthritis Res Ther; 2009; 11(6):R170. PubMed ID: 19909548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
    Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
    Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
    Ann Rheum Dis; 2016 Jun; 75(6):1081-91. PubMed ID: 26511996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
    Genovese M; Westhovens R; Meuleners L; Van der Aa A; Harrison P; Tasset C; Kavanaugh A
    Arthritis Res Ther; 2018 Mar; 20(1):57. PubMed ID: 29566740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.
    Verhoeven MMA; Tekstra J; Welsing PMJ; Pethö-Schramm A; Borm MEA; Bruyn GAW; Bos R; Griep EN; Klaasen R; van Laar JM; Lafeber FPJG; Bijlsma JWJ; de Hair MJH; Jacobs JWG
    Rheumatology (Oxford); 2020 Sep; 59(9):2325-2333. PubMed ID: 31859346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.